Other Cancer Types
A summary of additional cancer settings where withaferin A has meaningful but thinner preclinical evidence.
WFA has preclinical evidence across several additional cancer types. These settings do not yet support the same level of confidence as breast or ovarian cancer, but they are not trivial.
Overview
Cancer type | Key signal | Evidence level |
|---|---|---|
Colorectal |
| Cell line and animal |
Osteosarcoma | Published Phase I oncology trial and pro-apoptotic preclinical work | Phase I human plus preclinical |
Prostate | G2/M arrest and proteomic target mapping | Cell line established |
Pancreatic | Oxaliplatin synergy and CSC-related signalling | Cell line only |
Cervical | HPV | Cell line and animal |
B-cell lymphoma |
| Cell line and animal |
Hepatocellular | Ferroptosis and resistance relevance via | Cell line and animal |
Thyroid | Sorafenib synergy | Cell line and animal |
Key references
Bolleddula J. et al. — Phase I osteosarcoma trial of withaferin A.
https://www.sciencedirect.com/science/article/pii/S0975947618307897
Sun S. et al. — colorectal cancer growth and metastasis work targeting HIF-1α and EMT.
https://www.archivesofmedicalscience.com/Withaferin-A-inhibits-colorectal-cancer-growth-and-metastasis-by-targeting,196381,0,2.html
Sarin N. et al. — pancreatic cancer chemoresistance and oxaliplatin synergy.
https://www.sciencedirect.com/science/article/pii/S0753332218330701
Gopalakrishnan R. et al. — anti-cancer activity of withaferin A in B-cell lymphoma.
https://uknowledge.uky.edu/microbio_facpub/159/
Guo J. et al. — hepatocellular-cancer and ferroptosis-relevant review context.
https://onlinelibrary.wiley.com/doi/10.1002/ptr.8090
What this means in practice
These settings expand the plausibility of WFA as a broad anticancer platform. They do not carry the same translational weight.
Osteosarcoma is the main exception because it has direct human Phase I relevance, even though efficacy remains unproven.
The others remain exploratory disease areas where mechanism is ahead of clinical translation.
Bottom line
These thinner signals matter most as evidence of breadth, not as proof of near-term clinical readiness.
Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14